CHI is delighted to announce a new and improved Oligonucleotide & Precision Therapeutics (OPT) Congress for 2019. To complement our 4th annual Oligonucleotide Discovery and Delivery conference we are introducing a 2 day program
dedicated to Oligonucleotide CMC and Regulatory Strategies. In addition, we deliver two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair.
Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout
the drug development process. Attend in 2019 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.
MARCH 26-27, 2019
4th Annual Oligonucleotide Discovery and Delivery: Optimizing Design, Delivery and Performance
Inaugural Oligonucleotide CMC and Regulatory Strategies: Accelerating Product Development and Commercial Success
MARCH 28, 2019
Inaugural New Frontiers in Gene Editing and Repair: Using CRISPR and Other Gene Editing Techniques to Drive Precision Medicine
2nd Annual Drug Discovery for Rare Diseases: Exploring New Technologies, Targets and Drug Modalities